Labcorp (NYSE:LH) has made significant headlines lately. In particular, Wall Street Zen has upgraded it to a 'Buy'. Labcorp also recently expanded its MRD Test Suite and announced an increase in its dividend, indicating a structural change in its investment case. Labcorp's shares underwent a three-month decline of 10.5% in valuation, but expanded cancer testing portfolio is now being reassessed. Furthermore, they recently announced their 2025 quarterly results, however, a funding crunch in the biotech sector has led them to cut their growth outlook for their research unit. QRG Capital Management Inc. has stock holdings of $878,000 in Labcorp. The next highlight was the selling of Labcorp shares by Massachusetts Financial Services Co. MA and Navera Investment Management Ltd. Additional news of significance includes their recent appointment of Victor Bulto to their Board of Directors, the acquisition of a significant amount of shares by SG Americas Securities LLC, and strong Q3 earnings reported in 2025. Combined with the strategic momentum of the bio-tech giant, this progress has sparked discussion regarding its valuation after breakthroughs in cancer diagnostics and AI-powered pathology, spearheading in oncology innovation.
Laboratory Corporation of America Holdings LH News Analytics from Tue, 11 Mar 2025 07:00:00 GMT to Sat, 24 Jan 2026 05:48:31 GMT - Rating 7 - Innovation 8 - Information 6 - Rumor 4
